Literature DB >> 11276078

Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.

B M Beyer1, R Zhang, Z Hong, V Madison, B A Malcolm.   

Abstract

A comparison of the DNA sequences from all available genotypes of HCV indicate that the active site residues of the NS3 protease are strictly conserved with the exception of positions 123 and 168, which border the S(4) subsite. In genotype 3, the canonic arginine and aspartic acid have been replaced with threonine and glutamine, respectively. To determine if these differences contribute to an altered specificity, we characterized single-chain NS3 proteases from strains 1a, 1b, and 3a with peptide substrates and product inhibitors on the basis of the natural cleavage junction sequences, in addition to polyprotein substrates derived from the 1a strain. No statistically significant differences in specificity were observed. To demonstrate that the active sites were actually different, we generated and evaluated peptide substrates with unnatural extended side-chains. These studies confirmed that there are measurable differences between the NS3 proteases of genotypes 1 and 3. Specifically, a 5-fold difference in K(i) was observed between the proteases from genotypes 1 and 3 when a D-Glu occupied P(5), and a 30-fold difference was seen when this position contained a D-homoglutamate. The contribution of residues 123 and 168 toward the altered specificity was then evaluated individually by site-directed mutagenesis. These mutants showed that potency differences within this series could be attributed to the residue that occupied position 123 of the protease. Modeling these unnatural substrate/mutant protease interactions, on the basis of cocrystal structures of enzyme-substrate complexes, provides a structural basis for these observations. Proteins 2001;43:82-88. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11276078

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  8 in total

1.  Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.

Authors:  Mark A Winters; Seth L Welles; Mark Holodniy
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Authors:  X Tong; A Arasappan; F Bennett; R Chase; B Feld; Z Guo; A Hart; V Madison; B Malcolm; J Pichardo; A Prongay; R Ralston; A Skelton; E Xia; R Zhang; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

5.  Increasing rate of cleavage at boundary between non-structural proteins 4B and 5A inhibits replication of hepatitis C virus.

Authors:  Morgan R Herod; Daniel M Jones; John McLauchlan; Christopher J McCormick
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

6.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

Authors:  Severine Margeridon-Thermet; Robert W Shafer
Journal:  Viruses       Date:  2010-12-01       Impact factor: 5.048

7.  Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.

Authors:  Christoph Welsch; Francisco S Domingues; Simone Susser; Iris Antes; Christoph Hartmann; Gabriele Mayr; Andreas Schlicker; Christoph Sarrazin; Mario Albrecht; Stefan Zeuzem; Thomas Lengauer
Journal:  Genome Biol       Date:  2008-01-23       Impact factor: 13.583

8.  Retraction Note: Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry.

Authors:  Mahim Khan; Waqar Rauf; Fazal-E- Habib; Moazur Rahman; Mazhar Iqbal
Journal:  World J Hepatol       Date:  2022-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.